Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Benda Anticipates 2008 Approval In India For Gene Therapy Product

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China-Based Benda Pharmaceuticals anticipates 2008 approval from India's Central Drugs Control Organization for its gene therapy product Gendicine for treatment of head and neck cancer. The company filed its application for the recombinant human Ad-p53 injection in November

You may also be interested in...



Sanofi-Aventis China R&D Head Frank Jiang On Forming A Fully Integrated Drug R&D Platform In China: An Interview With Pharmasia News

Sanofi-Aventis opened its doors in Shanghai in June 2005 with its China Clinical Research Unit, established to conduct high-quality clinical trials that would pass regulatory muster worldwide. The company recently expanded its R&D presence in the country by broadening its activities. Sanofi VP and China R&D Head Frank Jiang talked to PharmAsia News' Shanghai bureau about Sanofi's R&D strategy in China.

Sanofi-Aventis China R&D Head Frank Jiang On Forming A Fully Integrated Drug R&D Platform In China: An Interview With Pharmasia News

Sanofi-Aventis opened its doors in Shanghai in June 2005 with its China Clinical Research Unit, established to conduct high-quality clinical trials that would pass regulatory muster worldwide. The company recently expanded its R&D presence in the country by broadening its activities. Sanofi VP and China R&D Head Frank Jiang talked to PharmAsia News' Shanghai bureau about Sanofi's R&D strategy in China.

Benda’s Jiangling Plant Gets Production Approval

SHANGHAI - Benda's Jiangling plant has received approval from China's State FDA for the production of active pharmaceutical ingredients, the company announced Jan. 22

UsernamePublicRestriction

Register

OM005385

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel